Drug details

Olumiant (baricitinib tablets)

type of DMARDs, JAK Inhibitors

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe rheumatoid arthritis (RA) who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist.

This drug may have the following side effects:

• nausea,
• upper respiratory tract infections (common cold, sinus infections),
• cold sores (herpes simplex), and
• shingles (herpes zoster)

The following drugs are related to Olumiant, either as a replacement or used together:

• Humira (adalimumab injection solution for subcutaneous administration)
• Bebtelovimab (bebtelovimab)
• Novavax (covid-19 vaccine for intramuscular injection)
• Simponi Aria (golimumab for infusion)
• Simponi Injection (golimumab injection)
• Inflectra (infliximab-dyyb intravenous injection)
• Renflexis (infliximab-abda injection)
• Mobic (meloxicam)
• Trexall (methotrexate)
• Rasuvo (methotrexate non-pyrogenic solution for a single subcutaneous injection)
• Rheumatrex (methotrexate tablets)
• Rinvoq (upadacitinib extended-release tablets)
• Xevudy (sotrovimab injection)